Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

Jason Liebowitz, MD, FACR  |  July 15, 2022

In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsRheumatoid ArthritisVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)axial spondyloarthritis (SpA)eosinophilic granulomatosis with polyangiitis (EGPA)EULARmicroscopic polyangiitis (MPA)Rheumatoid Arthritis (RA)

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2022

Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAFDA approvalRheumatoid Arthritis (RA)RiabniRituxanrituximabrituximab-arrxU.S. Food and Drug Administration (FDA)

Pearls of Wisdom from an Expert: Challenging ILD Cases with a Pulmonologist-Rheumatologist

Samantha C. Shapiro, MD  |  June 17, 2022

Erin Wilfong, MD, PhD, shared her niche expertise in connective tissue disease ILD (CTD-ILD) via case-based learning during a session of the 2022 ACR Education Exchange.

Filed under:ConditionsMeeting ReportsOther ACR meetings Tagged with:ACR Education ExchangeILDinterstitial lung disease (ILD)lungspulmonologistrheumatologist

Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

Samantha C. Shapiro, MD  |  June 15, 2022

No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

Filed under:ConditionsSystemic Sclerosis Tagged with:ILDinterstitial lung disease (ILD)lungsnintedanibSclerodermaSSc-ILDsystemic sclerosis (SSc)tocilizumab

Gene Profiling May Predict Treatment Response in Refractory Rheumatoid Arthritis

Marilynn Larkin  |  June 7, 2022

NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say.1 “We believe this study is a paradigm shift in precision medicine in RA,” Dr. Costantino…

Filed under:ConditionsRheumatoid Arthritis Tagged with:geneticGenetic researchrefractory rheumatoid arthritisRheumatoid Arthritis (RA)rituximabsynovial biopsiestocilizumab

Case Report: MPA Hiding in Plain Sight

Benjamin Aronow, MD, Eduardo Mantovani Cardoso, MD, Steffi Thomas, DO, Prashant Grover, MD, & Weishali Joshi, MD  |  May 12, 2022

The COVID-19 pandemic has filled hospitals with patients with rapidly progressive respiratory failure and diffuse bilateral opacities on chest X-ray.1 Additionally, many patients with severe COVID-19 develop acute kidney injury and require dialysis.2 Pulmonary-renal syndromes are also important to consider in this setting. Although alveolar hemorrhage is a cardinal feature of this syndrome, many patients…

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumcase reportCOVID-19Fellowsmicroscopic polyangiitis (MPA)Polyangiitis

Remission Definitions in RA: Common Questions & Implications for Clinical Practice

Samantha C. Shapiro, MD  |  May 5, 2022

A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyC-reactive protein (CRP)Disease Activity Score (DAS)patient global assessment (PGA)RA Resource CenterRemissionRheumatoid Arthritis (RA)

Tissue Evaluation: Understanding Rheumatoid Arthritis Inside & Out

Jason Liebowitz, MD, FACR  |  March 23, 2022

At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Clifton Bingham, MD, delves into research into rheumatoid arthritis at the cellular level.

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:Advances in the Diagnosis and Treatment of the Rheumatic Diseases meetingbiopsymacrophagesRheumatoid Arthritis (RA)

Get Expert Advice on Compliance Safeguards Post-Pandemic

Carina Stanton  |  March 18, 2022

Payer audits and coding scrutiny are in full swing after an influx of fraudulent claims during the COVID-19 pandemic. Make sure your coding practices are in compliance to protect your revenue.

Filed under:Billing/CodingEducation & TrainingMeeting ReportsOther ACR meetings Tagged with:ACR Education ExchangeCoding & BillingCompliance

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 46
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences